Strong Revenue Growth
BrainsWay generated $11.4 million in revenue in Q4 2024, marking a 27% year-over-year increase. For the full year, 2024 revenue reached $41 million, a 29% increase compared to 2023.
Increased System Placements
The company shipped 75 Deep TMS systems in Q4 2024, representing a 25% increase compared with the same period last year, and the total installed base reached 1,353 systems.
Positive Financial Performance
BrainsWay reported a gross margin of 75% for both Q4 and full year 2024, with positive net income for the fifth consecutive quarter and positive adjusted EBITDA for the sixth consecutive quarter.
Promising Market Expansion
The company expanded its market presence in key regions like Canada, Asia, India, and Europe, and saw increased sales for OCD treatment, the first TMS therapy approved for this condition.
Innovative Clinical Developments
Notable advancements include the FDA's decision to extend the age range for MDD treatment, and positive data on Deep TMS combined with psychedelic therapies for depression.
Robust Cash Position
BrainsWay ended 2024 with $69.4 million in cash, supported by a $20 million equity financing from Valor Equity Partners.